Evidence map›Paper›PMID 35318519›Full record

ArticleAnnals of surgical oncology2022

Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study.

Abdelkader Taibi, Olivia Sgarbura, Martin Hübner, Sylvia M Bardet, Mohammed Alyami, Naoual Bakrin, Sylvaine Durand Fontanier, Clarisse Eveno, Johan Gagniere, Basile Pache and 6 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Advances in the management of peritoneal malignancies.Nature reviews. Clinical oncology · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 3 countries.

Abdelkader TaibiDigestive Surgery Department, Dupuytren Limoges University Hospital, Limoges, France. abdelkader.taibi@hotmail.Fr.ORCID http://orcid.org/0000-0002-1036-6474
Olivia SgarburaDepartment of Surgical Oncology, Cancer Institute Montpellier (ICM), University of Montpellier, Montpellier, France.
Martin HübnerDepartment of Visceral Surgery, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland.
Sylvia M BardetCNRS, XLIM, UMR 7252, University Limoges, Limoges, France.
Mohammed AlyamiDepartment of General Surgery and Surgical Oncology, Lyon Sud University Hospital, Pierre Benite, France.
Naoual BakrinDepartment of General Surgery and Surgical Oncology, Lyon Sud University Hospital, Pierre Benite, France.
Sylvaine Durand FontanierDigestive Surgery Department, Dupuytren Limoges University Hospital, Limoges, France.
Clarisse EvenoDepartment of General Surgery, University Hospital Lille, Lille, France.
Johan GagniereDepartment of General Surgery, University Hospital Clermont-Ferrand, Clermont-Ferrand, France.
Basile PacheDepartment of Visceral Surgery, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland.
Marc PocardINSERM U1275, CAP Paris-Tech, Carcinomatosis Peritoneum Paris Technology, Lariboisière Hospital, AP-HP, Paris 7 -Diderot University, Sorbonne Paris Cité, Paris, France.
François QuenetDepartment of Surgical Oncology, Cancer Institute Montpellier (ICM), University of Montpellier, Montpellier, France.
Hugo Teixeira FarinhaDepartment of Visceral Surgery, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Lausanne, Switzerland.
Emilie ThibaudeauDepartment of Surgical Oncology, Institut de Cancérologie de l'Ouest, Saint Herblain, France.
Frederic DumontDepartment of Surgical Oncology, Institut de Cancérologie de l'Ouest, Saint Herblain, France.
Olivier GlehenDepartment of General Surgery and Surgical Oncology, Lyon Sud University Hospital, Pierre Benite, France.
Centre National de la Recherche Scientifique · FRHôpital Lyon Sud · FRUniversity of Lausanne · CHInserm · FRInstitut de Cancérologie de l'Ouest · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FRLille’s Cardiology Hospital · FRUniversité de Montpellier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis retrospective multicenter cohort study compared the feasibility and safety of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC-Ox) with or without intraoperative intravenous 5-fluorouracil (5-FU) and leucovorin (L).

methodsOur study included consecutive patients with histologically proven unresectable and isolated colorectal peritoneal metastases (cPM) treated with PIPAC-Ox in seven tertiary referral centers between January 2015 and April 2020. Toxicity events and oncological outcomes (histological response, progression-free survival, and overall survival) were compared between patients who received intraoperative intravenous 5-FU/L (PIPAC-Ox + 5-FU/L group) and patients who did not (PIPAC-Ox group).

resultsIn total, 101 patients (263 procedures) were included in the PIPAC-Ox group and 30 patients (80 procedures) were included in the PIPAC-Ox + 5-FU/L group. Common Terminology Criteria for Adverse Events v4.0 grade 2 or higher adverse events occurred in 48 of 101 (47.5%) patients in the PIPAC-Ox group and in 13 of 30 (43.3%) patients in the PIPAC-Ox + 5-FU/L group (p = 0.73). The complete histological response rates according to the peritoneal regression grading score were 27% for the PIPAC-Ox + 5-FU/L group and 18% for the PIPAC-Ox group (p = 0.74). No statistically significant differences were observed in overall or progression-free survival between the two groups.

conclusionsThe safety and feasibility of PIPAC-Ox + 5-FU/L appears to be similar to the safety and feasibility of PIPAC-Ox alone in patients with unresectable cPM. Oncological outcomes must be evaluated in larger studies.

Indexed as

Colorectal NeoplasmsPeritoneal NeoplasmsAerosolsCohort StudiesFeasibility StudiesFluorouracilHumansLeucovorinOxaliplatinAerosolsFluorouracilLeucovorinOxaliplatin

Identifiers

PMID35318519
OpenAlexW4220918476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.